Animal Health Investment Europe: Applications Open for Emerging Companies Seeking Investment
5.11.2019 09:00:00 EET | Business Wire | Press release
Calling all animal health and nutrition innovators: entries are now open for the 2020 Innovation Showcase at the Animal Health Investment Europe show. The premier investment forum showcases the most exciting innovation in animal health and nutrition, connecting emerging companies with financial investors and strategic corporate partners.
Applications for the Innovation Showcase close Monday 18th November 2019 and can be made online (click here).
The Innovation Showcase is a globally recognised opportunity for emerging companies to present in front of the industry’s most influential figures and investors. 20 start-ups, hand-picked by the Selection Committee, which includes Cindy Cole, Partner, Digitalis Ventures, Maarten Goossens, Co-founder & Principal, Anterra Capital and Spencer Swayze, Managing Director, Paine Schwartz Partners, LLC, take to the main stage to introduce themselves and their innovations and achievements.
This year, the 20 presenting companies will be split into two distinguishable sections that will run across the show:
- 10 start-ups will present their innovations in the companion animal & pet care space.
- 10 start-ups will present their innovations in the production animal & animal agri-tech space.
Entry is free of charge and is strongly encouraged from all emerging companies looking for investment or partners: from pre-revenue to late-stage start-ups. Applications are welcomed from; pharmaceuticals, vaccines, novel therapeutics, digital platforms, devices & diagnostic tools, nutritional health & feed additives, pet health and medical, genetics, robotics & automation, data analytics & sensors, immunostimulants, microbiome peptides, insect protein, bacterial phages. Applications can be made here.
Finalists will be announced early December and will have a chance to share a synopsis of their achievements and goals to compete for the industry Award for Innovation.
Last year’s Innovation Showcase saw Rex Animal Health and Proteon Pharmaceuticals win the innovation awards for animal health and animal nutrition, respectively.
Animal Health Innovation EU will take place from 25-26 February 2020 at Etc. venues, 133 Houndsditch, London, UK.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191104005777/en/
Contact information
Press contact for Animal Health Investment Europe:
Sarah Rowlands
Marketing Manager, Kisaco Research
sarah.rowlands@kisacoresearch.com
+44 (0)203 696 2929
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newmont Reports 2025 Mineral Reserves of 118.2 Million Gold Ounces and 12.5 Million Tonnes of Copper19.2.2026 23:08:00 EET | Press release
Newmont Corporation (NYSE: NEM, ASX: NGT, PNGX: NEM) (Newmont or the Company) reported gold Mineral Reserves ("reserves") of 118.2 million attributable ounces at the end of 2025 compared to 134.1 million attributable ounces at the end of 2024, mainly driven by the divestment of assets in 2025. Newmont's portfolio includes significant reserves from other metals, including 12.5 million attributable tonnes of copper reserves and 442 million attributable ounces of silver reserves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219894602/en/ Percentage of Gold Reserves by Jurisdiction "In 2025, Newmont maintained its position of having the industry's largest gold reserve base, declaring 118 million ounces of reserves, representing decades of production life with meaningful upside," said Natascha Viljoen, Newmont's President and Chief Executive Officer. "Through the disciplined application of technical rigor in our leading expl
Unveiling NVIDIA Solution Center: Grid Dynamics’ Family of AI Solutions to Cut Costs for Retail and Manufacturing19.2.2026 23:05:00 EET | Press release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics), a premier AI transformation partner for the Fortune 1000, today announced the launch of its NVIDIA Solution Center. This suite of ready-to-deploy AI applications helps retail and manufacturing enterprises move away from costly, recurring SaaS licenses and subscription fees toward high-performance, NVIDIA-powered solutions. Learn more by reading NVIDIA’s recent announcement. The NVIDIA Solution Center is derived from Grid Dynamics’ proven successful deployments at customers across the retail and manufacturing industries. The suite leverages NVIDIA’s software components including Metropolis, Omniverse, and Nemotron. All solutions offer flexible deployment at the edge, in on-premises datacenters, or in the cloud, enabling customers to achieve an optimal balance between inference cost, latency, privacy, and other operational requirements. The suite covers the following use cases, tailored to the needs of retail and manufacturing
Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results19.2.2026 23:01:00 EET | Press release
Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the 2025 fourth quarter and fiscal year ended December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219293814/en/ Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results “Our fourth quarter results reflect solid execution and continued accelerating sales growth, adjusted for the Oracle PeopleSoft support and services wind down. We grew our core Rimini Support™ subscription billings and launched our next generation Agentic AI ERP solutions that can be easily and quickly deployed over the top of existing ERP Software without the cost or risk of unnecessary ERP Software upgrades, migrations or replatforming,” said
Ares Management Prices European Direct Lending CLO II at Over €300 Million19.2.2026 19:25:00 EET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely of directly originated and actively managed loans issued by over 70 middle-market companies predominantly based in Western Europe and primarily operating in resilient industries. The instrument is weighted towards senior-secured floating rate loans and will be rated by S&P and KBRA. Ares believes EDL CLO II is among the first multi-currency middle-market CLOs in Europe. “We are pleased to successfully price our second European Direct Lending CLO in less than 12 months as we continue building on our nearly 20 years of corporate direct lending experience in Europe,” said Michael Dennis, Partner and Co-Head of
Positive Phase 3 Data Demonstrate Potential for ENTYVIO ® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis19.2.2026 19:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), show vedolizumab’s promising efficacy and safety profile in a patient population where therapy options remain limited.With KEPLER, Takeda is continuing to generate deeper scientific insights and identify additional patient populations who may benefit from vedolizumab, a cornerstone therapy for adults with ulcerative colitis. Vedolizumab is marketed under the trade name ENTYVIO®*. “Ulcerative colitis is a life-altering diagnosis for young patients and their families, often leaving t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom